Zacks Investment Research Upgrades Landos Biopharma (NASDAQ:LABP) to Buy

Landos Biopharma (NASDAQ:LABP – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday, Zacks.com reports. The firm currently has a $0.75 target price on the stock. Zacks Investment Research‘s price target points to a potential upside of 24.58% from the company’s previous close.

According to Zacks, “Landos Biopharma Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. Landos Biopharma Inc. is based in BLACKSBURG, Va. “

Several other brokerages have also recently commented on LABP. Raymond James decreased their price objective on shares of Landos Biopharma from $24.00 to $9.00 and set an “outperform” rating for the company in a research note on Friday, March 25th. Jefferies Financial Group cut shares of Landos Biopharma from a “buy” rating to a “hold” rating in a research note on Tuesday, April 12th. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $21.61.

LABP stock opened at $0.60 on Tuesday. The firm has a 50 day moving average of $1.18 and a 200 day moving average of $3.61. The stock has a market capitalization of $24.23 million, a PE ratio of -0.55 and a beta of 1.49. Landos Biopharma has a 52 week low of $0.55 and a 52 week high of $16.17.

Landos Biopharma (NASDAQ:LABP – Get Rating) last announced its quarterly earnings data on Thursday, May 12th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.02). Sell-side analysts anticipate that Landos Biopharma will post -1.4 earnings per share for the current year.

Several large investors have recently bought and sold shares of the company. Acadian Asset Management LLC purchased a new stake in Landos Biopharma in the 4th quarter worth $39,000. Morgan Stanley increased its holdings in Landos Biopharma by 1,337.0% in the 2nd quarter. Morgan Stanley now owns 6,912 shares of the company’s stock worth $81,000 after acquiring an additional 6,431 shares in the last quarter. Goldman Sachs Group Inc. purchased a new stake in Landos Biopharma in the 4th quarter worth $84,000. Wells Fargo & Company MN increased its holdings in Landos Biopharma by 382.6% in the 2nd quarter. Wells Fargo & Company MN now owns 9,526 shares of the company’s stock worth $110,000 after acquiring an additional 7,552 shares in the last quarter. Finally, Bank of America Corp DE increased its holdings in Landos Biopharma by 2,001.3% in the 4th quarter. Bank of America Corp DE now owns 31,225 shares of the company’s stock worth $150,000 after acquiring an additional 29,739 shares in the last quarter. 66.53% of the stock is owned by hedge funds and other institutional investors.

Landos Biopharma Company Profile (Get Rating)

Landos Biopharma, Inc, a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis; NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1 (NOD-like), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and LABP-104, an orally-active and systemically bioavailable small molecule therapeutic candidate that targets LANCL2 agonist for the treatment of systemic lupus erythematosus and rheumatoid arthritis (RA).

See Also